Wechselwirkungen · Sugammadex Adroiq
Sugammadex Adroiq 100 mg/mL solution for injection · Abschnitt 4.5 · PDF-Seite 7
HOS-150941 · Präparat HOS-100426
Due to the administration of certain medicinal products after sugammadex, theoretically rocuronium or vecuronium could be displaced from sugammadex. As a result, recurrence of neuromuscular blockade might be observed. In this situation the patient must be ventilated. Administration of the medicinal product which caused displacement should be stopped in case of an infusion. In situations when potential displacement interactions can be anticipated, patients should be carefully monitored for signs of recurrence of neuromuscular blockade (approximately up to 15 minutes) after parenteral administration of another medicinal product occurring within a period of 7.5 hours after sugammadex administration.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): vecuronium (HOS-119611) rocuronium (HOS-119610)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-16T17:21:00Z · SHA-256 e7be1eb58d32faccb389767c0e9e5884057016dec53c72705ce1121f897cfb97 · Passage 3c7322b1e60b7ce2efd1a780a625495f7e076e927ce9fe57d7ed9382ef573ed2 · Zeichen 933–1638 im Abschnitt